Scotland is to have its own £15.8m artificial intelligence health research centre, which promises to enable better patient diagnosis, treatment and outcomes.
The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics, to be known as iCAIRD, brings together a pan-Scotland collaboration of 15 partners from across academia, the NHS, and industry.
Today (Tuesday 6 November), Greg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will announce that UK Research and Innovation will invest £10million in iCAIRD as part of the Industrial Strategy Challenge Fund.
Partner companies in the University of Glasgow-led pan Scotland consortium, Canon Medical Research Europe Ltd and Philips, along with six SMEs, will provide more than £5M of additional funding to support iCAIRD. iCAIRD will be a Scottish centre of excellence and focus on the application of AI in digital diagnostics, ultimately enabling better and earlier diagnosis and more efficient treatment for patients. It is also predicted that iCAIRD will create new jobs centred around AI and digital technology in healthcare.
Centred at the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital, iCAIRD bring together teams across Scotland – in Aberdeen, St Andrews and Edinburgh – to enable joined-up academic and commercial technology development, alongside academic researchers locally and nationally.
The centre’s work will deliver significant benefits for patients through the development of solutions for more rapid treatment for stroke; expert chest x-ray reading; rapid and more accurate diagnosis in gynaecological disease and colon cancer; and partly automated mammogram analysis for breast cancer screening.
Making use of the capability of modern computers to process the large amounts of data gathered in NHS healthcare clinics, iCAIRD will also allow clinicians, health planners and industry to work together and ultimately solve healthcare challenges more quickly and efficiently, and in a way that completely protects patients’ identities.
Building on significant investment across Scotland, iCAIRD will integrate with Health Data Research UK (HDRUK) and the national Picture Archiving Communication System (PACS) for radiology.
Founding iCAIRD partners are (in alphabetical order): Bering Ltd, Canon Medical Research Europe Ltd, Cytosystems Ltd, DeepCognito Ltd, Glencoe Software, HDRUK Scotland and Scotland’s National and Regional Safe Havens, Intersystems, Kheiron Medical Technology, NHS Grampian, NHS Greater Glasgow & Clyde, NHS National Services Scotland, NVidia, Philips, University of Aberdeen, University of Edinburgh, University of Glasgow (hub site of iCAIRD) and University of St Andrews.
Professor David Harrison, Principal Investigator for the project, based in St Andrews but with visiting professorships in both Glasgow and Edinburgh, said: “I am delighted that iCAIRD has been awarded £10m from Innovate UK. With our pan-Scotland approach, we will build on existing strengths and deploy AI within NHS Scotland to transform diagnostics and healthcare in Scotland to improve outcomes for patients.
“This is a genuine collaboration between researches from Scottish universities, the NHS, and industry partners who are also contributing large sums to enable this project to be a success. Our aim is to transform digital diagnostic healthcare in Scotland, in order to benefit patients and make processes more streamlined and modern for the NHS.”
Professor Dame Anna Dominiczak, Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, said: “The formation of iCAIRD is a great coup for Scotland and its people, and further positions Scotland’s ability to be a global leader in Precision Medicine.
“iCAIRD epitomises our ‘triple helix’ approach to healthcare innovation and Precision Medicine by developing research and innovation concurrently in industry, the NHS and academia.
“By locating at the Clinical Innovation Zone at the Queen Elizabeth University Hospital, alongside partners in industry and the NHS, iCAIRD will also drive open innovation and encourage further industry collaborations, building upon existing expertise and infrastructure for driving AI-related healthcare and precision medicine innovation for the benefit of patients, NHS and the economy.”
Ken Sutherland, President of Canon Medical Research Europe Ltd, said: “Canon Medical are excited to be part of the iCAIRD proposal and we look forward to working with the other partners in the consortium to create novel AI solutions that can be proven to deliver better healthcare outcomes for the people of Scotland. As such this project epitomises our Made for Life philosophy, a long standing commitment from Canon Medical towards our partners, patients, and you.
“Our strong focus on putting patients at the centre of everything we do drives our motivation to work with our customers and partners to meet this common goal and find new ways to develop intelligent solutions that meet growing needs to be more efficient and achieve results fast with increased clinical confidence.”